Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: J Mol Cell Cardiol. 2015 Jul 23;86:75–84. doi: 10.1016/j.yjmcc.2015.07.014

Fig. 2.

Fig. 2

Role of NOS and ET receptors in the adverse action of ET-1. Administration of NOS inhibitor (L-NAME) did not affect the adverse action of ET-1 (10 pmol/L) on vasodilations to serotonin (A) and adenosine (B). However, blockade of ETA receptors by BQ-123 (1 μmol/L) prevented ET-1-induced reduction of vasodilations in response to serotonin and adenosine. The ETB receptor antagonist BQ-788 (0.1 μmol/L) had no impact on the adverse effect of ET-1. 5 vessels for each set of experiments. *P < 0.05 vs. Control, two-way ANOVA followed by the Bonferroni multiple range test. The ETA receptors (green staining) were detected in the vascular wall (C; n = 3). The expression of eNOS protein (red staining) was used to localize the endothelium. Scale bar indicates 50 μm.